- Home
- TNMG vs ELEV Comparison
TNMG vs ELEV Comparison
Compare TNMG & ELEV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNMG
- ELEV
- Stock Information
- Founded
- TNMG 2023
- ELEV 2019
- Country
- TNMG Japan
- ELEV United States
- Employees
- TNMG N/A
- ELEV N/A
- Industry
- TNMG
- ELEV Biotechnology: Pharmaceutical Preparations
- Sector
- TNMG
- ELEV Health Care
- Exchange
- TNMG NYSE
- ELEV Nasdaq
- Market Cap
- TNMG 20.1M
- ELEV 22.8M
- IPO Year
- TNMG N/A
- ELEV 2021
- Fundamental
- Price
- TNMG $0.51
- ELEV $0.38
- Analyst Decision
- TNMG
- ELEV Hold
- Analyst Count
- TNMG 0
- ELEV 6
- Target Price
- TNMG N/A
- ELEV $1.77
- AVG Volume (30 Days)
- TNMG 503.8K
- ELEV 2.0M
- Earning Date
- TNMG 08-01-2025
- ELEV 08-05-2025
- Dividend Yield
- TNMG N/A
- ELEV N/A
- EPS Growth
- TNMG N/A
- ELEV N/A
- EPS
- TNMG N/A
- ELEV N/A
- Revenue
- TNMG $48,493,897.00
- ELEV N/A
- Revenue This Year
- TNMG N/A
- ELEV N/A
- Revenue Next Year
- TNMG N/A
- ELEV N/A
- P/E Ratio
- TNMG N/A
- ELEV N/A
- Revenue Growth
- TNMG 35.31
- ELEV N/A
- 52 Week Low
- TNMG $0.26
- ELEV $0.22
- 52 Week High
- TNMG $34.08
- ELEV $3.28
- Technical
- Relative Strength Index (RSI)
- TNMG N/A
- ELEV 62.35
- Support Level
- TNMG N/A
- ELEV $0.38
- Resistance Level
- TNMG N/A
- ELEV $0.39
- Average True Range (ATR)
- TNMG 0.00
- ELEV 0.01
- MACD
- TNMG 0.00
- ELEV 0.00
- Stochastic Oscillator
- TNMG 0.00
- ELEV 85.00
About TNMG TNL MEDIAGENE
TNL Mediagene is principally engaged in digital advertising, integrated marketing, marketing survey, artificial intelligence technology, data analysis, content service platform and production of audio-visual programs. Geographically, the company generates the majority of its revenue from Taiwan.
About ELEV Elevation Oncology Inc. Common stock
Elevation Oncology Inc is an oncology company focused on the development of selective cancer therapies to treat patients across a range of solid tumors with unmet medical needs. Its product candidate, EO-3021 (also known as SYSA1801 or CPO102), is an ADC comprised of a fully human anti-Claudin 18.2 immunoglobulin G1 (IgG1) monoclonal antibody (mAb) site-specifically conjugated with a cleavable linker to the cytotoxic monomethyl auristatin E (MMAE) payload. Claudin 18.2 is overexpressed in several types of cancers, including gastric, esophageal, pancreatic, ovarian and lungon.